Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin
Huan Yu, Vincent C Woo Department of Medicine, Division of Endocrinology and Metabolism, Health Sciences Centre, University of Manitoba, Winnipeg, MB, Canada Aims: The aim of this article is to review the safety and efficacy data of dapagliflozin, saxagliptin, and their combination in the m...
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Dove Medical Press
2017
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/dbb34e9ada984dba808d4585df353ff7 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| id |
oai:doaj.org-article:dbb34e9ada984dba808d4585df353ff7 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:dbb34e9ada984dba808d4585df353ff72021-12-02T00:21:58ZEmerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin1178-7007https://doaj.org/article/dbb34e9ada984dba808d4585df353ff72017-07-01T00:00:00Zhttps://www.dovepress.com/emerging-use-of-combination-therapies-for-the-management-of-type-2-dia-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Huan Yu, Vincent C Woo Department of Medicine, Division of Endocrinology and Metabolism, Health Sciences Centre, University of Manitoba, Winnipeg, MB, Canada Aims: The aim of this article is to review the safety and efficacy data of dapagliflozin, saxagliptin, and their combination in the management of patients with type 2 diabetes. Evidence for the use of the single-tablet combination formulation is also presented. Methods: A nonsystematic literature review was performed using the Ovid, PubMed, and Google Scholar databases. Results: The addition of dapagliflozin/saxagliptin to metformin can lower mean hemoglobin A1c by as much as 1.47% and lead to weight loss of 0.5–2.0 kg. The risk of genital infections with combination therapy is lower than observed with dapagliflozin alone, suggestive of a protective effect. Adverse event risk at 52-week follow-up was not increased beyond that seen with either monotherapy. Conclusion: Dapagliflozin/saxagliptin combination is generally well tolerated and is an effective tool in helping patients with diabetes improve glycemic control. Keywords: SGLT2 inhibitor, DPP4 inhibitor, single-tablet combination, diabetes mellitusYu HWoo VCDove Medical PressarticleSGLT2-inhibitorDPP4-inhbitorfixed-dose pilldiabetes mellitusSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 10, Pp 317-332 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
SGLT2-inhibitor DPP4-inhbitor fixed-dose pill diabetes mellitus Specialties of internal medicine RC581-951 |
| spellingShingle |
SGLT2-inhibitor DPP4-inhbitor fixed-dose pill diabetes mellitus Specialties of internal medicine RC581-951 Yu H Woo VC Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin |
| description |
Huan Yu, Vincent C Woo Department of Medicine, Division of Endocrinology and Metabolism, Health Sciences Centre, University of Manitoba, Winnipeg, MB, Canada Aims: The aim of this article is to review the safety and efficacy data of dapagliflozin, saxagliptin, and their combination in the management of patients with type 2 diabetes. Evidence for the use of the single-tablet combination formulation is also presented. Methods: A nonsystematic literature review was performed using the Ovid, PubMed, and Google Scholar databases. Results: The addition of dapagliflozin/saxagliptin to metformin can lower mean hemoglobin A1c by as much as 1.47% and lead to weight loss of 0.5–2.0 kg. The risk of genital infections with combination therapy is lower than observed with dapagliflozin alone, suggestive of a protective effect. Adverse event risk at 52-week follow-up was not increased beyond that seen with either monotherapy. Conclusion: Dapagliflozin/saxagliptin combination is generally well tolerated and is an effective tool in helping patients with diabetes improve glycemic control. Keywords: SGLT2 inhibitor, DPP4 inhibitor, single-tablet combination, diabetes mellitus |
| format |
article |
| author |
Yu H Woo VC |
| author_facet |
Yu H Woo VC |
| author_sort |
Yu H |
| title |
Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin |
| title_short |
Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin |
| title_full |
Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin |
| title_fullStr |
Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin |
| title_full_unstemmed |
Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin |
| title_sort |
emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/dbb34e9ada984dba808d4585df353ff7 |
| work_keys_str_mv |
AT yuh emerginguseofcombinationtherapiesforthemanagementoftype2diabetesndashfocusonsaxagliptinanddapagliflozin AT woovc emerginguseofcombinationtherapiesforthemanagementoftype2diabetesndashfocusonsaxagliptinanddapagliflozin |
| _version_ |
1718403834418561024 |